-
Bioorg. Med. Chem. Lett. · Jul 2014
ReviewRecent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus.
- Elisabeth Defossa and Michael Wagner.
- Lead Generation to Candidate Realization, Sanofi Deutschland GmbH, Industriepark Hoechst, 65926 Frankfurt, Germany. Electronic address: Elisabeth.Defossa@sanofi.com.
- Bioorg. Med. Chem. Lett. 2014 Jul 15;24(14):2991-3000.
AbstractDespite the availability of established medication for treatment of type 2 diabetes mellitus (T2DM) there still remains a significant unmet need for new effective, oral antidiabetic agents that improve glycemic control while maintaining an excellent safety profile. In this regard the FFA1 receptor has emerged as an attractive target in recent years. Activation of the FFA1 receptor has been shown to not only amplify glucose induced insulin secretion from pancreatic beta cells but also to stimulate incretin secretion from intestinal endocrine cells. The current review highlights on the latest developments and clinical data from evolving research on the potential of FFA1 agonists as effective treatment for T2DM.Copyright © 2014. Published by Elsevier Ltd.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..